"We are proud to work with developers of products to stem the abuse of opioids which is a serious health crisis in the United States and elsewhere" said Dr. Anthony Costantino, Ph.D., President and CEO of DRUGSCAN©. "In-vitro studies like these should help developers create safer opioid products that deter the common methods of abuse".
The following poster will be presented during the PAINWeek 2016 poster session on Thursday, September 8 from 7:00 pm - 9:00 pm:
Optimization of a Smoking-Simulation Technique to Investigate Smoke-Ability of Opioids from Pharmaceutical Formulations.
Authors: Paul Fort, Amanda Hobe, Jennifer Poshkus, Jessica Baehr, Chris Altomare, Hongzhe Wang, Daniel Leach, Greg Gironda and Abdel Halim
DRUGSCAN is a leader in laboratory-based abuse-deterrent studies (CAT.one™), clinical and forensic toxicology, medication monitoring, and drug detection laboratory services. DRUGSCAN has been certified by the Substance Abuse and Mental Health Services Administration (SAMHSA) since 1989 and is accredited by the College of American Pathologists (CAP), ensuring consistently high levels of service, compliance with regulations, and achievement of the highest standards of accuracy, professionalism and responsiveness. To learn more about DRUGSCAN and their CAT.one™ capabilities, please visit drugscan.com or call 800-235-4890
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/drugscan-to-present-scientific-data-at-the-painweek-2016-conference-300319481.html